Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
BIIB Quote, Financials, Valuation and Earnings
Last price:
$177.32
Seasonality move
:
3.49%
Day range:
$176.39 - $182.23
52-week range:
$110.04 - $202.41
Dividend yield:
0%
P/E ratio:
19.43x
P/S ratio:
2.63x
P/B ratio:
1.38x
Volume:
1.3M
Avg. volume:
1M
1-year change:
35.04%
Market cap:
$25.1B
Revenue:
$9.5B
EPS (TTM):
$8.81
Analysts' Opinion
-
Consensus RatingBiogen, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 13 Buy ratings, 20 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $207.33, Biogen, Inc. has an estimated upside of 16.74% from its current price of $177.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $150.00 representing 15.42% downside risk from its current price of $177.34.
Fair Value
-
According to the consensus of 34 analysts, Biogen, Inc. has 16.74% upside to fair value with a price target of $207.33 per share.
BIIB vs. S&P 500
-
Over the past 5 trading days, Biogen, Inc. has underperformed the S&P 500 by -10.2% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Biogen, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Biogen, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Biogen, Inc. reported revenues of $2.2B.
Earnings Growth
-
Biogen, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Biogen, Inc. reported earnings per share of -$0.33.
Enterprise value:
28.9B
EV / Invested capital:
--
Price / LTM sales:
2.63x
EV / EBIT:
11.93x
EV / Revenue:
3.03x
PEG ratio (5yr expected):
0.47x
EV / Free cash flow:
14.66x
Price / Operating cash flow:
12.75x
Enterprise value / EBITDA:
9.02x
Gross Profit (TTM):
$6.3B
Return On Assets:
4.52%
Net Income Margin (TTM):
13.56%
Return On Equity:
7.36%
Return On Invested Capital:
5.34%
Operating Margin:
17.06%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $9.4B | $9.3B | $9.5B | $2.3B | $2.2B | |
| Gross Profit | $6.4B | $6.2B | $6.3B | $1.5B | $1.5B | |
| Operating Income | $1.6B | $2.1B | $2.4B | $390.6M | $372.1M | |
| EBITDA | $2.1B | $2.8B | $3.2B | $614.6M | $572.3M | |
| Diluted EPS | $7.98 | $11.18 | $8.81 | $1.83 | -$0.33 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.9B | $9.8B | $6.9B | $7.5B | $9B | |
| Total Assets | $23.9B | $24.6B | $26.8B | $28B | $29.4B | |
| Current Liabilities | $4.3B | $3.3B | $3.4B | $5.5B | $3.3B | |
| Total Liabilities | $12.9B | $11.2B | $12B | $11.3B | $11.2B | |
| Total Equity | $11B | $13.4B | $14.8B | $16.7B | $18.3B | |
| Total Debt | $7.6B | $6.6B | $7.3B | $6.6B | $6.6B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.5B | $2.9B | $2.2B | $760.9M | $511.9M | |
| Cash From Investing | -$4.1B | -$799.2M | -$1.4B | -$18.6M | -$1.2B | |
| Cash From Financing | $137M | -$683.5M | -$301.9M | $7.9M | -$137M | |
| Free Cash Flow | $1.2B | $2.5B | $2B | $694.6M | $401.7M | |
BIIB
Sector
Market Cap
$25.1B
$23.9M
Price % of 52-Week High
87.61%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
0.03%
-1.88%
1-Year Price Total Return
35.04%
-18.29%
Beta (5-Year)
0.162
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$185.01
200-day SMA
Buy
Level
$159.23
Bollinger Bands (100)
Sell
Level
170.83 - 189.43
Chaikin Money Flow
Buy
Level
135M
20-day SMA
Sell
Level
$184.89
Relative Strength Index (RSI14)
Sell
Level
40.61
ADX Line
Sell
Level
13.96
Williams %R
Neutral
Level
-71.4252
50-day SMA
Sell
Level
$186.02
MACD (12, 26)
Sell
Level
-1.06
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
330.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2019)
Buy
CA Score
(Annual)
Level (0.561)
Buy
Beneish M-Score
(Annual)
Level (-2.6367)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-2.0451)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Stock Forecast FAQ
In the current month, BIIB has received 13 Buy ratings 20 Hold ratings, and 1 Sell ratings. The BIIB average analyst price target in the past 3 months is $207.33.
-
Where Will Biogen, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Biogen, Inc. share price will rise to $207.33 per share over the next 12 months.
-
What Do Analysts Say About Biogen, Inc.?
Analysts are divided on their view about Biogen, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Biogen, Inc. is a Sell and believe this share price will drop from its current level to $150.00.
-
What Is Biogen, Inc.'s Price Target?
The price target for Biogen, Inc. over the next 1-year time period is forecast to be $207.33 according to 34 Wall Street analysts, 13 of them rate the stock a Buy, 1 rates the stock a Sell, and 20 analysts rate the stock a Hold.
-
Is BIIB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Biogen, Inc. is a Hold. 20 of 34 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BIIB?
You can purchase shares of Biogen, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Biogen, Inc. shares.
-
What Is The Biogen, Inc. Share Price Today?
Biogen, Inc. was last trading at $177.32 per share. This represents the most recent stock quote for Biogen, Inc.. Yesterday, Biogen, Inc. closed at $177.34 per share.
-
How To Buy Biogen, Inc. Stock Online?
In order to purchase Biogen, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get BIIB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BIIB
Sector
P/E ratio
19.43x
21.37x
PEG ratio
0.47x
-0.01x
P/B ratio
1.38x
1.72x
Price / LTM sales
2.63x
1.45x
Growth Metrics
BIIB
Sector
Revenue growth
-6.71%
3.44%
Earnings growth
-118.25%
15.03%
Revenue (5-year growth)
-5.06%
6.25%
Earnings forecast
$3.03
-$0.22
Profitability
BIIB
Sector
Profitability FY 2025
$6.5B
$2.4M
Return on invested capital
5.34%
-33.32%
Return on assets
4.52%
-29.45%
Return on equity
7.36%
-40.29%
Earnings Date
Last Earnings Date
Feb
6
Next Earnings Date
Apr
30
Estimated Next Earnings Date
May
8
Balance Sheet
BIIB
Sector
Total cash
$3.8B
$25.7M
Short term investments
--
$22.7M
Total assets
$29.4B
$70.6M
Long term debt
$6.6B
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
